Roger Colman is resigning from the Interleukin Genetics Inc. board on Dec. 30.
He was nominated by Pyxis Innovations Inc. following an investment in Interleukin Genetics. Colman is also retiring from Pyxis.
Pyxis Innovations can appoint two directors to the Interleukin Genetics board but is waiving off its right to name a replacement for Colman.
Joseph Landstra continues to represent Pyxis on the Interleukin board.